Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan

Phase 1

Completed

• Conditions: Chronic Myelogenous Leukemia
• Interventions: Drug: Dasatinib

• Registration Number: NCT00337454
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

This study is composed of Phase I and Phase II part. Phase I part: The objective is to evaluate the safety of BMS-354825 in subject with chronic phase Chronic Myelogenous Leukemia (CML). Dosage of BMS-354825 will be 50 mg BID, 70 mg BID or 90 mg BID. Phase II part: The objective is to evaluate the efficacy of BMS-354825. dosage will be decided according to the results of Phase I part. Treatment period will be 6 months for subjects with chronic phase CML, and 3 months for subjects with accelerated phase or blast phase CML and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Detailed Description

Not available

Study Timeline

• Study Start: 2005-07
• Study First Submitted: 2006-06-14
• Study First Submitted QC: 2006-06-15
• Study First Posted: 2006-06-16
• Primary Completion: 2007-03
• Study Completion: 2007-03
• Disposition First Submitted: 2010-02-04
• Disposition First Submitted QC: 2010-02-04
• Disposition First Posted: 2010-02-08
• Status Verified: 2011-04
• Last Update Submitted: 2011-04-07
• Last Update Posted: 2011-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• Philadelphia chromosome positive or bcr-abl gene positive
• Chronic Myelogenous Leukemia (CML)
• Subjects must have primary or acquired resistance to imatinib mesylate or have intolerance of imatinib mesylate
• Philadelphia Chromosome Positive Acute Lymphoblastic leukemia (Ph+ALL)
• Subjects must have primary or acquired resistance to chemotherapy or have intolerance of chemotherapy
• Performance status (general conditions) specified by the Eastern Cooperative Oncology Group: 0-2
• Men and women, ages 20 - 75
• Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 3 months after the study in such a manner that the risk of pregnancy is minimized

Exclusion Criteria

• Subjects who are eligible and willing to undergo transplantation at pre-study
• Women who are pregnant or breastfeeding
• Uncontrolled or significant cardiovascular disease
• History of significant bleeding disorder unrelated to CML or ALL
• Adequate hepatic function
• Adequate renal function
• Medication that increase bleeding risk
• Medication that change heart rhythms
• Subjects who are compulsorily detained for legal reasons or treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
B1	Dasatinib	-
B2	Dasatinib	-
A1	Dasatinib	-
A3	Dasatinib	-
B3	Dasatinib	-
A2	Dasatinib	-

Primary Outcome Measures

Name	Time	Method
Evaluate the safety of BMS-354825 administered orally twice daily for 4 weeks, evaluate the efficacy of BMS-354825 as defined by cytogenetic response for subjects with chronic phase CML, and as defined by hematologic response

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetic profiles, cytogenetic response and hematologic response, BCR-ABL point mutations and biochemical assays of BCR-ABL, safety, time to and duration of hematologic and cytogenetic response
response

Trial Locations

Locations (1)

Local Institution; 🇯🇵 Tokyo, Japan